Dodatkowe przykłady dopasowywane są do haseł w zautomatyzowany sposób - nie gwarantujemy ich poprawności.
Systemic treatment for the primary breast cancer did not alter these findings.
Confirmation of a prognostic index in primary breast cancer.
Free access to "Estrogen receptor of primary breast cancers: evidence for intracellular proteolysis"
Women who have had breast cancer are at increased risk of a second primary breast cancer, compared with risk in the general population.
All the paraffin-embedded sections of the resected primary breast cancers were assessed by immunohistochemistry staining for Met.
When these patients are treated with local excision, or as having primary breast cancer, 2- to 10-year survival has been obtained in approximately 50% of patients.
The Nottingham Prognostic Index in primary breast cancer.
This study led to a drastic reduction in use of radical mastectomy, to 5 percent from 75 percent of the operations done for primary breast cancer.
Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer.
In other words, antigens on the surface of the primary breast cancer cells were changing, and this change was allowing the cancer to spread into the lymph nodes.
It is a complication of primary breast cancer, usually occurring several years after resection of the primary breast cancer.
We have previously demonstrated the overexpression and hormone-independent activation of the IGF-IR in primary breast cancers [ 42 ] .
The use of these drugs as primary breast cancer prophylaxis should not be adopted until results are available from trials performed in populations of women without prior breast cancer.
Rosselli Del Turco M, Palli D, Cariddi A, et al.: Intensive diagnostic follow-up after treatment of primary breast cancer.
In a transgenic mouse model of cancer, black cohosh did not increase incidence of primary breast cancer, but increased metastasis of pre-existing breast cancer to the lungs.
In June 1977, she was the only lay member appointed to a ten-member National Institutes of Health (NIH) panel that evaluated treatment options for primary breast cancer.
Miki Y, Katagiri T, Kasumi F, et al.: Mutation analysis in the BRCA2 gene in primary breast cancers.
Coombes RC, Hall E, Gibson LJ, et al.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
It is particularly important that the surgeons should perform only breast operations, and that the centre should perform a minimum of 150 primary breast cancer operations per year, because expert knowledge comes only through experience.
Women with a personal history of invasive breast cancer, ductal carcinoma in situ, or lobular carcinoma in situ have a 0.6% to 1.0% estimated annual risk of developing a new primary breast cancer.
The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial compared anastrozole, tamoxifen, and the combination when used as an adjuvant HT after treatment of the primary breast cancer.
Albain KS, Green SJ, Ravdin PM, et al.: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814).
A prospective study from the Netherlands evaluated long-term psychological outcomes of offering women with breast cancer genetic counseling and, if indicated, genetic testing at the onset of breast radiation for treatment of their primary breast cancer.
Women with a breast cancer associated with a BRCA mutation have up to a 40% probability of developing a new primary breast cancer within 10 years following initial diagnosis if they did not receive tamoxifen treatment or have an oopherectomy.
Henderson IC, Berry DA, Demetri GD, et al.: Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.